Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The development of accurate and easy-to-use continuous glucose monitoring (CGM) improved diabetes treatment by providing additional temporal information on glycemia and glucose trends to patient and physician. Although CGM enables users to lower their average glucose level without an increased incidence of hypoglycemia, this comes at the price of additional patient effort. Automation of insulin administration, also known as closed-loop (CL) or artificial pancreas treatment, has the promise to reduce patient effort and improve glycemic control. CGM data serve as the conditional input for insulin automation devices. The first commercial product for partial automation of insulin administration used insulin delivery shutoff at a predefined glucose level. These systems showed a reduction in hypoglycemia. Insulin-only CL devices show increased time spent in euglycemia and a reduction of hypo- and hyperglycemia. Improved glycemic control, coinciding with a minor decrease in hemoglobin A1c level, was confirmed in recent long-term home studies investigating these devices, paving the way for pivotal studies for commercialization of the artificial pancreas. Although the first results from dual-hormone CL systems are promising, because of increased cost of consumables of these systems, long-term head-to-head studies will have to prove superiority over insulin-only approaches. Now CL glucose control for daily use might finally become reality. Improved continuous glucose sensing technology, miniaturization of electrical devices, and development of algorithms were key in making this possible. Clinical adoption challenges, including device usability and reimbursement, need to be addressed. Time will tell for which patient groups CL systems will be reimbursed and whether these devices can deliver the promise that they hold.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J., & Alva, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0378 · Cited by 685
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“Two randomized controlled trials were performed investigating low glucose suspend (LGS) (Medtronic, Northridge, CA), Bergenstal et al. 23 showed reduced incidence and duration of nonsevere hypoglycemia, whereas Ly et al. 24 showed reduced incidence and duration of nonsevere and severe hypoglycemia…”
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 2×
“The relation among wear time of CGM, baseline HbA1c, and HbA1c lowering was later confirmed by a meta-analyses of Pickup et al. 20 A Cochrane meta-analysis 21 showed that CGM technology, mostly studied in conjunction with CSII (SAP), can improve glucose control by means of a reduction in HbA1c level without increase of…”
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411 · cited 1×
“…were performed investigating low glucose suspend (LGS) (Medtronic, Northridge, CA), Bergenstal et al. 23 showed reduced incidence and duration of nonsevere hypoglycemia, whereas Ly et al. 24 showed reduced incidence and duration of nonsevere and severe hypoglycemia compared with the control arm.”
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Circadian Variability of Insulin Sensitivity: Physiological Input for In Silico Artificial Pancreas
Visentin, R., Dalla Man, C., Kudva, Y. C., Basu, A., & Cobelli, C. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0192 · Cited by 113
Cited by
Electrochemical Glucose Sensing: Is There Still Room for Improvement?
Witkowska Nery, E., Kundys, M., Jeleń, P. S., & Jönsson-Niedziółka, M. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03151 · Cited by 292
Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes
Stewart, Z. A., Wilinska, M. E., Hartnell, S., Temple, R. C., Rayman, G., Stanley, K. P., Simmons, D., Law, G. R., Scott, E. M., Hovorka, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602494 · Cited by 279
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm
Messer, L. H., Berget, C., & Forlenza, G. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0105 · Cited by 100
Metadata
- Authors
- Kropff, J., & DeVries, J. H.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2016-02
- Volume
- 18
- Issue
- S2
- Pages
- S2-53-S2-63
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2252544533
- Cited by
- 96
- References
- 9
- FWCI
- 20.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects. https://app.cochat.ai/papers/10.1089/dia.2015.0345
- The paper
- Kropff, J., & DeVries, J. H. (2016). Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2015.0345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.